Brown, Lisle/Cummings, Inc. Allakos Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Allakos Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 150 shares of ALLK stock, worth $103. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150
Previous 150
-0.0%
Holding current value
$103
Previous $189,000
20.63%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ALLK
# of Institutions
103Shares Held
77.2MCall Options Held
70.7KPut Options Held
2.8K-
Bvf Inc San Francisco, CA16.6MShares$11.4 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$4.24 Million0.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT5MShares$3.45 Million0.21% of portfolio
-
Black Rock Inc. New York, NY4.72MShares$3.26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.79MShares$2.62 Million0.0% of portfolio
About Allakos Inc.
- Ticker ALLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,726,096
- Market Cap $58.5M
- Description
- Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...